Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions (NASDAQ:ARQT)
IvelinRadkov/iStock via Getty Images Mizuho cut its rating of Arcutis Biotherapeutics (NASDAQ:ARQT) to neutral and slashed its price target, citing ...
IvelinRadkov/iStock via Getty Images Mizuho cut its rating of Arcutis Biotherapeutics (NASDAQ:ARQT) to neutral and slashed its price target, citing ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.